Dermatomyositis with inclusion body myositis pathology.
The pathogenic role of inflammation in inclusion body myositis (IBM) remains uncertain. A 63-year-old man developed a severe, rapidly progressive myopathy with clinical features typical of dermatomyositis (DM), but muscle pathology was typical of IBM. Treatment with prednisone and methotrexate resulted in complete remission of symptoms. Together with two similar cases reported previously, this case suggests that the inflammatory process of DM may trigger the pathologic changes of IBM.
Layzer
Robert
R
Department of Neurology, Box 0114, UCSF, University of California, San Francisco, California 94143, USA. rlayzer@sbcglobal.net
Lee
Han Sung
HS
Iverson
Donald
D
Margeta
Marta
M
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D003879:Dermatologic Agents / Q000627:therapeutic use; D003882:Dermatomyositis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D018485:Muscle Fibers, Skeletal / Q000378:metabolism / Q000473:pathology; D018979:Myositis, Inclusion Body / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000378:metabolism; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D015703:Antigens, CD; D003879:Dermatologic Agents; D011241:Prednisone; D008727:Methotrexate